Review Highlights Need to Align Peptide Engineering and Formulation for Long-Acting Injectable Therapies
Key Points
- A review says coordinating peptide engineering and formulation development early is essential for stable long-acting injectable therapies
- Strategies such as amino acid substitution, lipidation and PEG conjugation can help overcome rapid clearance and enzymatic degradation
- IVIVC models and Quality by Design principles can help achieve consistent, extended release profiles
Coordinating molecular engineering and formulation development early in the process is essential to creating stable, long-acting injectable peptide therapies, according to a review published in the Journal of Pharmaceutical Investigation. The authors examine the molecular modifications, delivery systems and analytical approaches needed to overcome the challenges associated with extending peptide drug release over longer dosing intervals.
Although peptide therapeutics offer high target selectivity and potent activity across metabolic, endocrine, oncology and rare disease indications, their development is complicated by rapid renal clearance, short systemic half-lives and susceptibility to enzymatic degradation. Long-acting injectable depots could reduce administration frequency and improve treatment adherence, but conventional sustained-release technologies are not always suitable for these molecules because of their hydrophilicity and structural sensitivity.
The review examines several molecular engineering approaches to improve peptide stability, prolong circulation and enhance compatibility with depot formulations. Strategies include amino acid substitutions, backbone modifications, terminal sequence extensions, conformational constraints, prodrug development and conjugation with polymers or lipids. Specific techniques such as D-amino acid substitution, lactam-bridge macrocyclization, lipidation and polyethylene glycol (PEG) conjugation can help address degradation pathways and influence how peptides interact with formulation matrices.
Formulation design presents another set of challenges, particularly during manufacturing and long-term storage. Peptide degradation can occur through chemical, physical or interactions with the depot environment, potentially affecting drug integrity and release performance. The authors emphasize the importance of selecting vehicle matrices and manufacturing processes that account for each molecule’s physicochemical characteristics. Sterility controls and specialized in vitro release testing under biorelevant conditions are also necessary to evaluate formulation performance over extended periods.
The review further highlights the importance of establishing reliable relationships between laboratory release testing and actual drug behavior in the body. In vitro–in vivo correlation (IVIVC) and in vitro–in vivo relationship (IVIVR) models can help connect dissolution and release profiles measured in controlled environments with in vivo pharmacokinetic performance. The authors also point to Quality by Design (QbD) principles and model-informed development as tools for controlling manufacturing variables, managing stability risks and achieving consistent release profiles.
Ultimately, the authors argue that long-acting peptide depots should be approached as integrated drug delivery systems rather than conventional sustained-release formulations. Aligning molecular modifications with formulation architecture from the earliest development stages can help address peptide-specific degradation risks, preserve product stability and achieve the intended dosing interval. The review provides a framework for developing long-acting peptide products across multiple therapeutic areas, with an emphasis on tailoring both the molecule and its delivery system to meet the requirements of the individual drug.
Learn more at https://doi.org/10.1007/s40005-026-00839-w.
Total Page Views: 1

















